IL17A and glioblastoma: In conclusion, due to its role in tumorigenesis, angiogenesis, and immune surveillance evasion, as well as its potential for aiding in the diagnosis and prognosis of GBM, targeting IL-17 or its signaling pathway shows promise as a novel therapeutic approach for treating GBM.